Mark A. Velleca - May 11, 2021 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
May 11, 2021
Transactions value $
-$585,401
Form type
4
Date filed
5/13/2021, 04:43 PM
Next filing
May 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $3.9K +10K +24.39% $0.39* 51K May 11, 2021 Direct
transaction GTHX Common Stock Sale -$191K -10K -19.61% $19.10* 41K May 11, 2021 Direct F1, F2
transaction GTHX Common Stock Options Exercise $3.9K +10K +24.39% $0.39* 51K May 12, 2021 Direct
transaction GTHX Common Stock Sale -$201K -10K -19.61% $20.07* 41K May 12, 2021 Direct F1, F3
transaction GTHX Common Stock Options Exercise $3.9K +10K +24.39% $0.39* 51K May 13, 2021 Direct
transaction GTHX Common Stock Sale -$205K -10K -19.61% $20.54* 41K May 13, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -2.96% $0.00 327K May 11, 2021 Common Stock 10K $0.39 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -3.06% $0.00 317K May 12, 2021 Common Stock 10K $0.39 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -3.15% $0.00 307K May 13, 2021 Common Stock 10K $0.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $18.69 and a high of $19.47. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 The price represents the weighted average price with a low of $19.80 and a high of $20.28. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
F4 The price represents the weighted average price with a low of $20.42 and a high of $20.895. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
F5 All shares underlying this option have vested.